SEARCH:      Monitor Keywords |  Custom RSS

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof November recently filed with US Patent Office 11/10

20100298528 - Cystine knot molecules: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the... Agent: Casimir Jones, S.c.

20100298529 - Manufacture and use of modified polysaccharide chitosan bonds and a process to improve the preparation of hes-medicinal substance compounds: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such... Agent: Klein, O'neill & Singh, LLP

20100298530 - Photoresponsive base having triazole skeleton: To provide a photocrosslinkable compound and a photocrosslinking agent which are capable of ligation of nucleic acids within a short period of time compared to the conventional cases, and to which modifications depending on the intended use can easily be made, and a method of producing the photocrosslinking agent. Nucleic... Agent: Squire, Sanders & Dempsey L.L.P.

20100298531 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298532 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298533 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298534 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298535 - Pmma binding peptides: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100298536 - Complex of cell translocational peptide and magnetic nanoparticles and use thereof: The present invention relates to a cell-penetrating peptide/fluorescence-labeled magnetic nanoparticle complex and the use thereof. More specifically, relates to a cell-penetrating peptide/fluorescence-labeled magnetic nanoparticle complex in which a cell-penetrating peptide is chemically linked to a fluorescence-labeled magnetic nanoparticle, such that fluorescence-labeled magnetic nanoparticle can be stably introduced directly into cells... Agent: Moore & Van Allen PLLC

20100298538 - Method for the stereoselective preparation of amino acid derivatives: The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C1-C8)-alkyl; followed by a hydrolysis reaction to obtain L-mesityl alanine, alternatively its enantiomer D-mesityl alanine and, optionally, subjecting said compound... Agent: Foley And Lardner LLP Suite 500

20100298537 - Process for the manufacture of persilylated peptides: Process for the manufacture of a peptide or peptide analog, which comprises (a) producing a persilylated peptide or persilylated peptide analogue by silylating a corresponding peptide by reaction with a silylating agent other than trimethylsilylcyanide, and (b) reacting a compound of formula (I) X-A-COOH wherein X is an amino protecting... Agent: Solvay C/o B. Ortego - Iam-nafta

20100298540 - Crystal structure of a marr family polypeptide: The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in Escherichia coli, and methods of crystallization of the MarR protein are described.... Agent: Mccarter & English, LLP Boston

20100298539 - Novel polypeptides and use thereof: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising a variant of the amino acid sequence of SEQ ID NO:1. Preferably, the polypeptide is a CHIPS variant wherein one or more of the following amino acids is... Agent: Morrison & Foerster LLP

20100298541 - Protein scaffolds: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.... Agent: Medimmune, LLC Patrick Scott Alban

20100298544 - Cdr-grafted anti-tissue factor antibodies and methods of use thereof: The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also... Agent: Philip S. Johnson Johnson & Johnson

20100298543 - Mammalian zcytor 11: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in pancreas, small intestine, colon and thymus. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation... Agent: Zymogenetics, Inc. Intellectual Property Department

20100298542 - Modified antibody constant region: The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region... Agent: Fish & Richardson PC

20100298545 - Epha2 agonistic monoclonal antibodies and methods of use thereof: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2... Agent: Medimmune, LLC Patrick Scott Alban

20100298546 - Dnas encoding tnf receptor family members: Polypeptide produced from human stromal cell line, the process for the preparation of the polypeptide, DNA encoding the polypeptide, vector carrying the DNA, host cell transformed by the vector, antibody of the polypeptide, and pharmaceutical composition containing the polypeptide or the antibody.... Agent: Sughrue-265550

20100298548 - Method for production of separation media: The present invention relates to a method for production of separation media using a so called Spinning Disc technology wherein the porosities of the beads are optimized in such a way that a desired biomolecule may be separated from a complex sample. The method comprises the following steps: a) feeding... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20100298547 - Methods for the directed expansion of epitopes for use as antibody ligands: The instant invention comprises a process for selecting and manufacturing antibodies useful for therapeutic, prophylactic, diagnostic or research purposes using epitope peptide mixtures synthesized by the solid phase synthesis, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute... Agent: Ropes & Gray LLP

20100298549 - Extraction method for target bio-molecule from a sample solution and fabrication of extraction module: An extraction method for a target bio-molecule of a sample solution is described. First, a substrate having a thermally responsive polymer brush immobilized thereon is provided. The thermally responsive polymer brush has a lower critical solution temperature (LCST). Thereafter, while the sample solution flows over the substrate, the temperature of... Agent: J C Patents

20100292434 - Igf-1r binding polypeptides and their use: This invention relates to polypeptides which bind to IGF-1R and to applications of those polypeptides in medicine, veterinary medicine, diagnostics and imaging.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100292435 - Insulinotropic peptide synthesis using solid and solution phase combination techniques: The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to couple the second fragment and the first fragment.... Agent: Grant D. Green Patent Department, M/s A2-250

20100292436 - Method for producing bivalirudin: e

20100292437 - Polypeptides useful for appetite suppression: The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between 12 and 13 amino acid residues in length and a mass of about 1249. The present invention also relates to a method of... Agent: Mcdermott, Will & Emery LLP Attn:IPDepartment

20100292438 - Proteinaceous compounds: A purified novel peptide micrin and its fragments are disclosed. The molecule has hormonal functions and has wide-ranging biological effects. Several uses are disclosed including its therapeutic potential in tissue reduction, tumour suppression, infertility and senescence. A micrin-recognising antibody and the micrin gene are also disclosed.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100292439 - Use of functionalized onium salts for peptide synthesis: p

20100292440 - Binding molecules for human factor viii and factor viii-like proteins: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of... Agent: Lando & Anastasi, LLP

20100292442 - Anti-il-17 receptor a neutralizing antibodies: The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A.... Agent: Amgen Inc. Law Department

20100292441 - Antibodies that specifically bind to gmad: The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic... Agent: Foley And Lardner LLP Suite 500

20100292443 - Humanized platelet activating factor antibody design using anti-lipid antibody templates: Methods for designing a humanized antibody to platelet activating factor are provided. These methods may be performed in silico.... Agent: Biotechnology Law Group 12707 High Bluff Drive

20100292444 - Novel prolactin compounds: The present invention relates to prolactin analogues, which analogues have increased resistance to deamidation.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100292446 - Isolation of dna, rna and protein from a single sample: The invention provides a method for the separation and purification of two or three cellular components selected from genomic DNA, RNA and proteins from a single biological sample. The method comprises generating an aqueous solution containing the cellular components by lysing cells with a lysis solution; contacting the aqueous solution... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20100292445 - Method for efficient purification of bionanocapsule: The present invention provides a method for purifying a heat-resistant bio-nanocapsule composed mainly of a protein produced by using a eukaryotic cell. The method comprises heat-treating a lysate of the eukaryotic cell to remove contaminant proteins, and then subjecting the resulting product to chromatography.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100292447 - Method and agent for refolding proteins: This invention relates to the use of ionic liquids comprising a cation with at least one electron donor region and one positively charged electrostatic region which are spatially distinct from each other for protein refolding and a method for refolding proteins using said ionic liquids.... Agent: Millen, White, Zelano & Branigan, P.C.

20100292448 - Sleeve valve: An extractor and a method using the extractor for extracting active principle from solid materials using an extracting fluid, said extractor comprising among others an extractor column (1), having a first side (22), a second side (23), a top side (24), and a bottom side (25); a top plate (10)... Agent: Jacobson Holman PLLC

20100286362 - Mammalian mdm2 binding proteins and uses thereof: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1... Agent: Licata & Tyrrell P.C.

20100286363 - Cyclic heptapeptide and use of the same: o

20100286364 - Glycosylated glycopeptide antibiotic derivatives:

20100286365 - Peptide-peptidase-inhibitor conjugates and methods of making and using same: Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity,... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100286366 - Polypeptide libraries with a predetermined scaffold: Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q, wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100286367 - Conjugates of soluble peptidic compounds with membrane-binding agents: The present invention provides, among other things, soluble derivatives of soluble polypeptides that incorporate membrane binding elements. Methods of making these soluble derivatives, and methods of using these soluble derivatives also are provided.... Agent: Reddie & Grose Perkins Coie LLP

20100286368 - Novel polypeptide and process for producing the same: The present invention provides a novel polypeptide or polypeptide derivative which has no risk of infection with a pathogen or propagation of a pathogenic factor and of an undesirable side effect, and which is useful as a carrier of various biologically-active substances or apatite, as well as a process for... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100286369 - Methods for generating polynucleotides having desired characteristics by iterative selection and recombination: A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to... Agent: Weaver Austin Villeneuve & Sampson LLP

20100286371 - Methods of activating clostridial toxins: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.... Agent: Allergan, Inc.

20100286370 - Novel fluorescent protein molecules: The present invention relates to novel fluorescent proteins and to methods of making these proteins and the uses thereof.... Agent: G Kenneth Smith

20100286372 - Pregnane x receptor compositions, crystals and uses thereof: The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.... Agent: Merck Patent Department (k-6-1, 1990)

20100286373 - Immunoglobulin affinity ligand: Provided is affinity chromatography carrier for an immunoglobulin that simultaneously has high immunoglobulin-binding capability and chemical stability and that can be produced at low cost. An immunoglobulin-binding protein in which an amino acid substitution for not only maximizing the number of lysine residues on the protein surface of helix 3... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100286374 - Method for making antibody fc-heterodimeric molecules using electrostatic steering effects: The invention relates to methods of making Fc-heterodimeric proteins or polypeptides. The invention also relates to the Fc-heterodimeric proteins or polypeptides themselves, including the individual polypeptide components that comprise the heterodimer. Nucleic acids encoding such polypeptides, expression vectors, and host cells. Moreover, the invention relates to pharmaceutical compositions comprising one... Agent: Amgen Inc. Law Department

20100286375 - Carrier molecules: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even... Agent: Robins & Pasternak

20100280220 - Gold binding peptides and shape-and size-tunable synthesis of gold nanostructures: The present invention relates to gold binding peptides and shape- and size-tunable synthesis of gold nanostructures. The present inventions are very useful for the production of well-designed, gold-based architectures. The size- and shape-specific gold nanostructure materials prepared by the present invention may find use as: highly conductive interconnections for single-electron... Agent: Clark & Elbing LLP

20100280221 - Peptide production and purification process: Processes for the synthesis and purification of a Gly-Gly-Val-Leu-Val-Gln-Pro-Gly octapeptide (SEQ ID NO 1).... Agent: Solvay C/o B. Ortego - Iam-nafta

20100280223 - method for determining and predicting protein autonomous folding: Techniques for determining an equilibrium structure of a protein in a predetermined environment, the protein having Ramachandran angles and a known denatured structure, are disclosed. In a preferred embodiment, a method is presented which involves determining a maximum RMS volume of the known denatured structure of the protein and calculating... Agent: Baker Botts L.L.P.

20100280222 - Clostridial neurotoxin compositions and modified clostridial neurotoxins: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In... Agent: Allergan, Inc.

20100280225 - Fungus-induced inflammation and eosinophil degranulation: This document relates to methods and materials involved in fungus-induced inflammation and eosinophil degranulation. For example, isolated nucleic acids encoding fungal polypeptides, fungal polypeptides, methods for assessing fungus-induced inflammation, methods for assessing eosinophil degranulation, and methods for identifying inhibitors of fungus-induced inflammation and/or eosinophil degranulation are provided.... Agent: Fish & Richardson P.C.

20100280224 - Marker sequences for multiple sclerosis and use thereof: The present invention relates to new marker sequences for multiple sclerosis and the diagnostic use thereof together with a method for screening of potential active substances for multiple sclerosis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for multiple sclerosis,... Agent: Connolly Bove Lodge & Hutz, LLP

20100280226 - Method for using nano carbon to refine collagen into nanoparticulate collagen: This invention relates to a method of using nano carbon to refine collagen into nanoparticulate collagen. As nano carbon particle are mixed into collagen, the pored structure of the nano carbon absorb and adhere to the collagen outer cell membrane and subsequently tears the collagen apart into nanoparticulates via ultrasound... Agent: Rosenberg, Klein & Lee

20100280227 - Polypeptides that bind br3 and uses thereof: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.... Agent: Clark & Elbing LLP

20100280228 - Purification of immunoconjugates: The present invention provides methods of purifying immunoconjugates.... Agent: Townsend And Townsend And Crew, LLP

20100280229 - Polypeptide: The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw